Ionis Pharmaceuticals Inc (IONS)

45.60
-0.38(-0.83%)
After Hours
45.50
-0.10(-0.22%)
- Real-time Data
  • Volume:
    549,252
  • Day's Range:
    45.19 - 46.22
  • 52 wk Range:
    25.04 - 48.82

IONS Overview

Prev. Close
45.98
Day's Range
45.19-46.22
Revenue
848.81M
Open
45.88
52 wk Range
25.04-48.82
EPS
-0.199
Volume
549,252
Market Cap
6.47B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
974,174
P/E Ratio
-
Beta
0.695
1-Year Change
40.23%
Shares Outstanding
141,941,338
Next Earnings Date
Nov 02, 2022
What is your sentiment on Ionis Pharma?
or
Market is currently closed. Voting is open during market hours.

Ionis Pharmaceuticals Inc News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Ionis Pharmaceuticals Inc Analysis

Ionis Pharmaceuticals Inc Company Profile

Ionis Pharmaceuticals Inc Company Profile

Employees
660

Ionis Pharmaceuticals, Inc. is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company is primarily focused on our cardiovascular and neurology franchises. Its products include SPINRAZA, TEGSEDI and WAYLIVRA. SPINRAZA is for the treatment of patients of all ages with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. TEGSEDI is for the treatment of patients with polyneuropathy caused by hereditary transthyretin (TTR), amyloidosis (hATTR), a debilitating, progressive, and fatal disease. WAYLIVRA is an antisense medicine indicated as an adjunct to diet in adult patients. The Company has over six medicines in Phase III studies for eight indications, which include Eplontersen (TTR), Olezarsen (ApoC-III), Donidalorsen (PKK), ION363 (FUS), Pelacarsen (Apo(a)) and Tofersen (SOD1). Its cardiovascular medicine in development includes Eplontersen, Olezarsen, Pelacarsen, ION449 (PCSK9), Fesomersen and IONIS-AGT-LRx.

Read More

Analyst Price Target

Average47.33 (+3.80% Upside)
High92
Low22
Price45.6
No. of Analysts18
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellSellBuyStrong BuyStrong Buy
Technical IndicatorsStrong SellSellSellStrong BuyStrong Buy
SummaryStrong SellSellNeutralStrong BuyStrong Buy
  • What’s about this stock? Any new therapies are coming out?
    0
    • I think shareholders needs a therapy now. BIIB / IONIS Tofersen (BIIB067) Phase 3 test did unsuccesful
      0
  • Absolutely underrated stock. See you in ten years or this fall when the product in cooperation with Biogen comes out
    0
    • Added 4000 at 34.4
      1
      • nice after market move!
        0
        • Give the anti-corona spray from marinomed-biotech some VC and invest in a pharma company which is heading to the moon:https://www.investing.com/equities/marinomed-biotech-agStudies are proving that the patented method of marinomed prevents infection with all Corona varietis including mutants. It also prevents other virus infections. They have many patents.  Do some good and get rich
          0
          • CARLSBAD, Calif., March 22, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced its partner, Roche, has decided to discontinue dosing in the Phase III GENERATION HD1 study of tominersen in manifest Huntington's disease (HD). The decision was based on the results of a pre-planned review of data from the Phase III study conducted by an unblinded Independent Data Monitoring Committee (iDMC). While there were no new or emerging safety signals identified for tominersen, the iDMC made its recommendation based on the investigational therapy's potential benefit/risk profile for study participants. Participants will continue to be followed for safety and clinical outcomes.
            0
            • this stock doesn't know what a green day looks like.
              0
              • ㅜㅜ~
                0